L-Carnitine for Injection

Pharmacological action L-carnitine is a natural substance in the body that is needed for mammalian energy metabolism. Its main function is to promote lipid metabolism. In the case of hypoxia and ischemia, acyl-CoA accumulates, long-chain acyl-carnitine also accumulates in the mitochondria, and free carnitine decreases due to large-scale consumption. Ischemia and hypoxia lead to a decrease in ATP levels, increased permeability of cell membranes and subcellular membranes, and accumulated acyl-CoA can cause changes in membrane structure, membrane phase collapse and cell death. In addition, during hypoxia, anaerobic glycolysis of sugar is the main process, and the accumulation of fatty acids leads to acidosis, ion disorder, and cell autolysis and death. A sufficient amount of free carnitine can allow the accumulated acyl-CoA to enter the mitochondria, reduce its inhibition of adenine nucleotide translocase, and enable oxidative phosphorylation to proceed smoothly. L-carnitine is the main energy source for muscle cells, especially myocardial cells. Many tissues and organs such as the brain and kidneys also rely mainly on fatty acid oxidation for energy. Carnitine can also increase the activity of NADH cytochrome C reductase and cytochrome oxidase, accelerate A The production of TP participates in the detoxification of certain drugs. For various tissue ischemia and hypoxia, L-carnitine improves the energy supply of tissues and organs by increasing energy production. Other functions of L-carnitine include: oxidation of medium-chain fatty acids; oxidation of fatty acid peroxidase; buffering the ratio of bound coenzyme A and free coenzyme A, generating energy from ketones, pyruvate, and amino acids (including branched-chain amino acids), removing the toxicity of excessive coenzyme A, and regulating blood ammonia concentration. Toxicological effects Mutagenicity tests on Salmonella typhimurium, Saccharomyces cerevisiae, and human yeast showed that L-carnitine was non-mutagenic. There are no long-term animal studies to evaluate whether L-carnitine has potential carcinogenicity. In reproductive studies of mice and rabbits, 3.8 times the human dose based on body surface area did not cause damage to the reproductive organs or fetuses. However, there are no sufficiently satisfactory studies on pregnant women. Since animal reproductive studies cannot predict human responses, this drug can only be used when pregnant women really need it.

L-Carnitine

This product is a white freeze-dried block

It is suitable for a series of complications caused by secondary carnitine deficiency in patients with chronic renal failure and long-term hemodialysis, such as cardiomyopathy, skeletal myopathy, arrhythmia, hyperlipidemia, hypotension and muscle spasm during dialysis.

The recommended starting dose after each hemodialysis is 10-20 mg/kg, dissolved in 5-10 ml of water for injection, and injected intravenously once every 2-3 minutes. When the plasma L-carnitine trough concentration is lower than normal (40-50 μmol/L), treatment should be started immediately, and the dose should be adjusted in the 3rd or 4th week of treatment (e.g. 5 mg/kg after hemodialysis).

The main symptoms are transient nausea and vomiting, with a special body odor. Nausea and gastritis do not occur often. Due to the complexity of the pathology causing these reactions, it is difficult to estimate the incidence of these reactions. Oral or intravenous injection of L-carnitine causes epileptic seizures. Regardless of whether there is a history of epilepsy, patients with previous epileptic seizures may induce epilepsy or aggravate epilepsy. In a double-blind, placebo-controlled trial of patients with chronic hemodialysis, the adverse reactions (without considering causality, only reactions with an incidence of ≥5%) mainly include: systemic system: chest pain, cold symptoms, headache, injection site reaction, pain, etc.; cardiovascular system: cardiovascular abnormalities, hypertension, hypotension, tachycardia, etc.; digestive system: diarrhea, indigestion, nausea, vomiting, etc.; endocrine system: thyroid abnormalities, etc.; blood and lymphatic system: anemia, etc.; metabolic system: hypercalcemia, hyperkalemia, hypervolemia, etc.; nervous system: dizziness, insomnia, depression, etc.; respiratory system: cough, pharyngitis, rhinitis, etc.; skin: itching, skin disease; urinary system: abnormal renal function, etc.

People who are allergic to this product are prohibited from using it.

Based on the potential clinical significance, patients receiving valproate may require an increase in the dose of L-carnitine.

Keep in a dark place, tightly closed, and store at room temperature.

1.0g

Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd.

• Founded in:

  1998-09-24

• Address:

  No. 389, Changbai Road, High-tech Development Zone, Yanji City, Jilin Province

• Tax NO.:

  912224017022762985

• Registered Funds:

  161.526808 yuan

• Email:

  Log in to view